The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Long-Term Follow-Up Results From the MURANO Trial in CLL

Nicole Lamanna, MD
Published Online:7:00 PM, Thu December 13, 2018

Nicole Lamanna, MD, associate professor and CLL director at the Columbia University Irving Medical Center, discusses the significance of the 3-year follow-up data for the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Patients had a progression-free survival (PFS) rate of 71% with a fixed duration of venetoclax (Venclexta) plus rituximab (Rituxan), compared to about 17% with bendamustine plus rituximab.

All patients had stopped venetoclax treatment at 2 years; these data were also broken down based on minimal residual disease (MRD) for further follow-up. In this analysis, Lamanna says there was a significant correlation between those who had undetectable disease and those who did very well.

Moving forward, the question remains whether these patients with disease still present should stop treatment or continue for a longer duration. While the PFS curve looks great, Lamanna notes that patients with high levels of MRD will still relapse and will need to be studied further. However, this was a good study to demonstrate fixed durations with venetoclax are possible.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.